Latest revenue
$72.4M
as of 2026-03-31
Latest net income
$-8.3M
as of 2026-03-31
Net margin
-11.5%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $173.3M
- Enterprise value
- $173.3M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $9.13
- 52-wk low
- $5.34
- Beta
- —
- Shares out
- 27.1M
5-year trend
What this company does
ITEM 1. BUSINESS General Inogen, Inc. is a medical technology business that primarily focuses on respiratory health. Inogen, Inc. develops, manufactures, and markets innovative portable oxygen concentrators (POCs) used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Our proprietary Inogen One® and Inogen Rove systems concentrate the air around the patient to offer a source of supplemental oxygen 24 hours a day, 7 days a week with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. While often used concomitantly with stationary oxygen concentrators and oxygen compressed…
AI summary unavailable — showing raw filing excerpt
Generated from INGN's filing dated 2024-03-01
Key risks
ITEM 1A. RISK FACTORS We operate in a rapidly changing environment that involves numerous uncertainties and risks. In addition to the other information included in this Annual Report on Form 10-K, the following risks and uncertainties may have a material and adverse effect on our business, financial condition, results of operations, or stock price. You should consider these risks and uncertainties carefully, together with all of the other information included or incorporated by reference in this Annual Report on Form 10-K. The risks and uncertainties described below may not be the only ones we face. If any of the risks or uncertainties we face were to occur, the trading price of our…
AI summary unavailable — showing raw filing excerpt
Generated from INGN's filing dated 2024-03-01
Profitability
Gross margin
44.2%
4.0%Operating margin
-8.7%
31.6%Net margin
-6.5%
39.0%Return on equity
-11.8%
32.5%Return on assets
-7.6%
37.1%Leverage
Debt / equity
0.55×
24.1%Debt / assets
35.6%
15.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $72.4M | +5.7% | $-8.3M | -34.8% | -11.5% |
Q4 2025 2025-12-31 | $121.9M | -1.1% | $-7.1M | +27.0% | -5.8% |
Q3 2025 2025-09-30 | $79.1M | +5.6% | $-5.3M | +11.2% | -6.7% |
Q2 2025 2025-06-30 | $79.2M | +6.4% | $-4.2M | +25.7% | -5.2% |
Q1 2025 2025-03-31 | $68.5M | +8.5% | $-6.2M | +57.6% | -9.0% |
Q4 2024 2024-12-31 | $123.3M | — | $-9.8M | — | -7.9% |
Q3 2024 2024-09-30 | $74.9M | +10.2% | $-6.0M | +87.0% | -8.0% |
Q2 2024 2024-06-30 | $74.4M | +8.9% | $-5.6M | +43.1% | -7.5% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Orthopedic, Prosthetic & Surgical Appliances & Supplies · SIC 3842
Your notes
Keep private notes on INGN — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns INGN
Institutional value
$41.6M
Total shares held
8.1M
Distinct holders
59
-73 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 1.6M | $10.2M | -69.8K (-4.1%) | Trimmed |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 1.0M | $6.4M | — | New |
| 3 | FEDERATED HERMES, INC. | 514.7K | $3.2M | +29.3K (+6.0%) | Added |
| 4 | DIMENSIONAL FUND ADVISORS LP | 509.8K | $3.2M | -201.6K (-28.3%) | Trimmed |
| 5 | JPMORGAN CHASE & CO | 427.7K | $2.6M | -41.6K (-8.9%) | Trimmed |
| 6 | PRUDENTIAL FINANCIAL INC | 369.1K | $2.3M | -89.0K (-19.4%) | Trimmed |
| 7 | Nuveen, LLC | 363.7K | $2.2M | -49.8K (-12.0%) | Trimmed |
| 8 | Peapod Lane Capital LLC | 258.6K | $1.6M | — | New |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | 225.6K | $1.4M | — | New |
| 10 | PERKINS CAPITAL MANAGEMENT INC | 199.6K | $1.2M | -18.1K (-8.3%) | Trimmed |
| 11 | UBS Group AG | 184.5K | $1.1M | +107.2K (+138.7%) | Added |
| 12 | Monaco Asset Management SAM | 175.7K | $1.1M | -22.5K (-11.3%) | Trimmed |
| 13 | VANGUARD FIDUCIARY TRUST CO | 153.8K | $950.7K | — | New |
| 14 | BNP PARIBAS FINANCIAL MARKETS | 126.0K | $778.9K | +8.7K (+7.4%) | Added |
| 15 | Bank of New York Mellon Corp | 112.9K | $697.9K | -10.8K (-8.7%) | Trimmed |
| 16 | TOCQUEVILLE ASSET MANAGEMENT L.P. | 93.3K | $576.9K | +0 (+0.0%) | No change |
| 17 | Connor, Clark & Lunn Investment Management Ltd. | 59.3K | $366.7K | -70.5K (-54.3%) | Trimmed |
| 18 | HSBC HOLDINGS PLC | 56.9K | $352.5K | -64.1K (-53.0%) | Trimmed |
| 19 | Invesco Ltd. | 56.1K | $346.7K | +2.7K (+5.1%) | Added |
| 20 | Assenagon Asset Management S.A. | 51.0K | $315.4K | +6.8K (+15.5%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once INGN's latest filing finishes processing.